CN1173731C - Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS - Google Patents
Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS Download PDFInfo
- Publication number
- CN1173731C CN1173731C CNB031462774A CN03146277A CN1173731C CN 1173731 C CN1173731 C CN 1173731C CN B031462774 A CNB031462774 A CN B031462774A CN 03146277 A CN03146277 A CN 03146277A CN 1173731 C CN1173731 C CN 1173731C
- Authority
- CN
- China
- Prior art keywords
- radix
- portions
- pulmonary fibrosis
- parts
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the application of a Chinese medicine composition for treating hepatic fibrosis of chronic hepatitis b in the preparation of a medicament used for treating the hepatic fibrosis, particularly the hepatic fibrosis caused by infective serious acute respiration syndrome (SARS), wherein the Chinese medicine composition is prepared from the following raw materials according to a conventional method: 110 to 130 portions of turtle shell, 80 to 90 portions of red peony root, 40 to 60% of angelica, 40 to 60 portions of panax notoginseng, 80 to 90 portions of lanceolata, 80 to 90 portions of astragalus, 40 to 50 portions of human placenta, 20 to 30 portions of Chinese caterpillar fungus, 130 to 150 portions of isatis root, 130 to 150 portions of weeping forsythiae capsule and 20 to 30 portions of zedoary. A preparation of the Chinese medicine composition is used for treating patients of the SARS hepatic fibrosis, the therapeutic effect of the composition is superior to that of the foundation treatment of simple western medicines, and the composition has the advantages of SARS mortality reduction, cure rate increase and disease course shortening.
Description
Invention field
The invention belongs to the application of a kind of known Chinese medicine composition in the medicine of other medical applications of preparation, particularly relate to a kind of application of Chinese medicine composition in the medicine of preparation treatment pulmonary fibrosis for the treatment of chronic hepatitis Bhepatic fibrosis, especially relate in a kind of treatment of preparation by the application in the medicine of the pulmonary fibrosis due to the SARS virus.
Background technology
Application number is 00105695.6, denomination of invention is " a kind of Chinese medicine preparation for the treatment of chronic hepatitis Bhepatic fibrosis and preparation method thereof ", open day is on November 15th, 2000, publication number is that the Chinese patent application of CN1273104A discloses a kind of Chinese medicine composition for the treatment of chronic hepatitis Bhepatic fibrosis, and it is made with following raw materials according: Carapax Trionycis 110-130 part, Radix Paeoniae Rubra 80-90 part, Radix Angelicae Sinensis 40-60 part, Radix Notoginseng 40-60 part, Radix Codonopsis 80-90 part, Radix Astragali 80-90 part, Placenta Hominis 40-50 part, Cordyceps 20-30 part, Radix Isatidis 130-150 part, Fructus Forsythiae 130-150 part, Rhizoma Curcumae 20-30 part.Preferably make: 25 parts of 120 parts of Carapax Trionycis (system), 85 parts of Radix Paeoniae Rubra, 50 parts of Radix Angelicae Sinensis, 50 parts of Radix Notoginseng, 85 parts of Radix Codonopsis, 85 parts of the Radixs Astragali, 45 parts of Placenta Hominiss, 25 parts of Cordyceps, 140 parts of Radix Isatidis, Fructus Forsythiae 140g part, Rhizoma Curcumae with following raw materials according.This Chinese medicine composition can be made with the conventional method in this area.Preferred following method: Carapax Trionycis, Radix Notoginseng, Radix Paeoniae Rubra, Cordyceps, Placenta Hominis are ground into fine powder; With Radix Angelicae Sinensis, Rhizoma Curcumae, Fructus Forsythiae distillating extracting oil, the aqueous solution after the distillation is stand-by, and medicinal residues are decocted with water 1-2 hour, filters, and filtrate and above-mentioned aqueous solution merge; Radix Codonopsis, the Radix Astragali and Radix Isatidis three flavors are decocted with water three times, each 1-2 hour, merge three times decocting liquid, filter to get filtrate; All filtrates and aqueous solution are merged, after the centrifugal roguing, under 50 ℃, be evaporated to the thick paste shape of relative density 1.25-1.30, vacuum drying becomes dry extract, is ground into fine powder, and with the fine powder and the right amount of auxiliary materials mixing of Carapax Trionycis, Radix Notoginseng, Radix Paeoniae Rubra, Cordyceps, the Placenta Hominis five tastes, make granule and dry, the volatile oil that adds above-mentioned Radix Angelicae Sinensis, Rhizoma Curcumae, Fructus Forsythiae three flavors again, mixing, compacting is in flakes.The full text of this application is cited as list of references by the application.In this patent application specification, there is not to disclose the purposes that this Chinese medicine composition is used for the treatment of pulmonary fibrosis.
The severe acute respiratory syndrome that rise to break out in mid-November, 2002, WHO is called " SARS ", be a kind of onset anxious, propagate the novel infectious disease fast, that case fatality rate is high, this disease has caused certain popular in more than 20 the countries concerned of the China and the world.Clear and definite cause of disease is a SARS virus, but present needleless still is to the medicine of the SARS cause of disease.Acute lung injury can occur in the SARS pathological process, pulmonary fibrosis can take place in the local pulmonary tissue, and has report Fibrotic performance to be arranged in some SARS rehabilitation patient lungs.In a single day pulmonary fibrosis takes place, and final final result is carrying out property of an interstitial lung collagen deposition, replaces normal pulmonary parenchyma structure, and lung tissue is further impaired, or the SARS state of an illness is increased the weight of, and increases mortality rate, or the SARS course of disease is prolonged, or makes SARS patient leave over sequela.Therefore, carrying out pulmonary fibrosis resistant in early days in the SARS treatment treats significant.
For interstitial pulmonary fibrosis, the traditional treatment of modern medicine comprises that adrenal gland's glucocorticoid treatment, immunosuppressant and fibrosis preparation treat separately or with hormons.Data shows that 10-30% hormone therapy conditions of patients improves, and only has a few peoples to cure
(1)The pulse methylprednisolone therapy impact treatment is compared with oral hormone, and not confirming has good curative effect
(2)Explanation heavy dose of hormone therapy SARS that uses in now clinical may not have good curative effect for interstitial pulmonary fibrosis.Immunosuppressant is applicable to that to the hormone therapy nonresponder hormone therapy has serious side effects person and high-risk complication patient.But toxic action is still the conventional obstacle of using immunosuppressant treatment.Wherein,, do not recommended to be used for the treatment of interstitial pulmonary fibrosis because of toxic action is big as methotrexate and chlorambucil etc.
(1)
Seeking new anti-fibrosis medicine aspect the treatment interstitial pulmonary fibrosis both at home and abroad at present.Some drugs finds that in vitro tests or animal experiment anti-fibrosis effect is arranged, and is applied to clinical on a small scale.It is synthetic that test finds that colchicine can suppress collagen, suppresses the somatomedin and the fibronectin in AM source, have report with it as a line medicine, share the treatment interstitial pulmonary fibrosis separately or with immunosuppressant
(3)Angiotensin-convertion enzyme inhibitor (ACEI) can suppress fibroblasts proliferation in rat model, alleviate pulmonary fibrosis
(4), but its curative effect remains further to be estimated.Usefulness erythromycin for treating bleomycin such as Li Yongchun cause pulmonary fibrosis model, find that erythromycin suppresses the NF-kB activity of AM, have suppressed lung tissue IL-I β and TGF-β mRNA and have expressed, and have alleviated alveolitis and fibrosis
(5), its curative effect still need be observed evaluation.Along with development of molecular biology, making by intervening effect of cytokines treatment pulmonary fibrosis becomes possibility, for example gamma interferon
(6)Deng cytokine therapy receive publicity.And utilize antisense oligonucleotide to carry out gene at present and seal the treatment of also trying out in pulmonary fibrosis.But these new therapies all need further evaluation.
The unexpected traditional Chinese medicine composition for treating pulmonary fibrosis of finding to use the disclosed treatment chronic hepatitis Bhepatic fibrosis of CN1273104A of the inventor, preferred Secondary cases pulmonary fibrosis, particularly have certain curative effect, thereby finished the present invention by pulmonary fibrosis due to severe acute respiratory syndrome (the being called for short SARS) virus.
Detailed description of the present invention
The Chinese medicine composition that purpose of the present invention just provides the disclosed treatment chronic hepatitis Bhepatic fibrosis of CN1273104A is being used for preparation treatment pulmonary fibrosis, preferred Secondary cases pulmonary fibrosis is particularly by the application in the medicine of pulmonary fibrosis due to the severe acute respiratory syndrome virus (abbreviation SARS virus).
" pulmonary fibrosis " described in the present invention comprises Secondary cases pulmonary fibrosis and the agnogenic idiopathic pulmonary fibrosis that a variety of causes (for example virus or bacterial infection, medicine, lonizing radiation, chemical stimulation etc.) causes.Pulmonary's pathological change of pulmonary fibrosis (comprising Secondary cases pulmonary fibrosis and idiopathic pulmonary fibrosis) all is with the alveolar wall cellular infiltration, thicken, interstitial fibers turns to characteristics.It is the common final result of various different cause of disease interstitial diseases, is the major reason of respiratory failure.After pulmonary fibrosis took place, lung compliance descended, and caused that restrictive ventilatory disorder, pneusomete total lung capacity lower, and produce anoxia; Interstitial lung proliferation of fibrous tissue, disperse cause that apart from increase the oxygen disperse reduces, and more increases the weight of anoxia.In clinical, show the abnormal pulmonary function of exceed system type ventilatory function obstacle and gas function of exchange obstacle like this, as carrying out property dyspnea, dry cough, cyanosis, moist rale appears in the base of lung, partial pressure of oxygen, blood oxygen saturation descends, two lung X lines performance lamellar, the netted shade of diffusivity.
The main clinic symptoms of infectious atypical pneumonia (SARS) is: hyperpyrexia (body temperature＞38 ℃); respiratory symptom (comprise cough, breathe hard, dyspnea); normal or the reduction (especially lymphopenia) of peripheral blood leucocyte; the T lymphocyte function is low, and chest x-ray or CT characteristics are the one-sided or bilateral wellability changes of pulmonary.Acute lung injury can appear in the SARS pathological process
(7), interstitial pulmonary fibrosis can take place in the local pulmonary tissue
(8)SARS postmortem patient's lung tissue can be observed a series of sexually transmitted disease (STD) reasons of carrying out in various degree and change
(9,10,11)Lung tissue inspection finds that whole lung all has the pathological change of DAD in various degree, and the latter comprises that pulmonary congestion (in early days), hyaline membrane form, and have the desquamation (peeling off) of pneumonocyte in inflammatory cell infiltration, the alveolar in the matter.Also show as the abnormal pulmonary function of restricted type ventilatory function obstacle and gas function of exchange obstacle in clinical, as carrying out property dyspnea, dry cough, cyanosis, moist rale appears in the base of lung, partial pressure of oxygen, blood oxygen saturation descends, two lung X lines performance lamellar, the netted shade of diffusivity.The formation of interstitial pulmonary fibrosis with increasing the treatment difficulty of SARS, delays patient's recovery, and the course of disease is prolonged, even mortality rate is raise.Infectious atypical pneumonia (being called for short SARS) when pulmonary fibrosis takes place, see by disease: tachypnea, and dyspnea with rapid respiration, unable, sweating, lose heart die Blausucht, agitation, deep red tongue, thin fur, thready and rapid pulse etc. are the card of deficiency in origin and excess in superficiality, and Chinese medical discrimination is that waste heat is unclear, impairment of both QI and YIN, blood stasis stagnation of phlegm.
Principle according to the traditional Chinese medical science " treating the same disease with different methods, treating different diseases with the same therapeutic principle ", my institute is during in March, 2003 to 2003, accepted patient SARS year June for medical treatment, the patient that priority is made a definite diagnosis SARS to 66 examples has carried out clinical observation, the Chinese medicinal composition preparation treatment SARS of the present invention that our application has dissolving blood stasis and detoxication, supplementing QI and nourishing YIN, hard masses softening and resolving has the patient that pulmonary fibrosis shows, and makes its clinical symptoms and sign, hypoxemia, chest imageology performance recovery and hospital stays more all be better than using merely the curative effect of doctor trained in Western medicine Primary Care.This shows that Chinese medicinal composition preparation of the present invention has the effect that the restrictive ventilatory disorder that improves pulmonary fibrosis and gas interchange disturbance, promotion fibrous tissue absorb, point out Chinese medicine composition of the present invention to can be used for the treatment of pulmonary fibrosis, especially for the treatment of the Secondary cases pulmonary fibrosis due to the viral infection, the treatment of the pulmonary fibrosis due to infecting in particular for SARS virus.Treatment for SARS can reach the attenuating mortality rate, improve cure rate, shortens the purpose of the course of disease.
Below the present invention is described better in preparation treatment pulmonary fibrosis medicine by the test example, the purposes of pulmonary fibrosis medicine aspect due to the preparation treatment SARS particularly.
The test example
Medicament sources:
Auspicious middle mongolian medicine limited company provides Chinese medicinal composition preparation of the present invention by Inner Mongol good fortune.
1 clinical data
1.1 physical data 66 routine patients all meet the health ministry severe acute respiratory syndrome and make a definite diagnosis diagnostic criteria.Use patient's 32 examples (medicine group of the present invention) of Chinese medicinal composition preparation of the present invention treatment, male 14 examples, women 18 examples: 17～74 years old age, average (30.1 ± 13.4) year: serious symptom 6 examples.Do not use patient's 34 examples (matched group) of Chinese medicinal composition preparation of the present invention, male 16 examples, women 18 examples; 19～73 years old age, average (35.3 ± 12.9) year; Serious symptom 8 examples.Credit is analysed by statistics, and physical data no difference of science of statistics (P＞0.05) such as two groups of ages, sex has comparability.
1.2 two groups of patients of diagnosis basis all meet the health ministry severe acute respiratory syndrome and make a definite diagnosis diagnostic criteria.The course of disease all has dyspnea performance (uncomfortable in chest or tachypnea) more than 7 days, and chest X ray or CT all see one-sided or bilateral patch shape or latticed shade.
1.3 it is not most that the Chinese medical discrimination Chinese medical discrimination is a pyretic toxicity, obstruction of collaterals by blood stasis, deficiency of qi and yin.Disease is seen: afternoon low grade fever, tachypnea are breathed heavily and suppressed obviously, and be very then stiff, or with cyanosis, agitation, dry cough or spitting of blood is arranged, xerostomia, shortness of breath and fatigue, sweating, deep red tongue, thin fur, thready and rapid pulse.
1.4 Therapeutic Method 66 routine patients all use the doctor trained in Western medicine Primary Care, as nutritional support, prednisolone, thymosin, Levofloxacin Mesylate Tablets, ribavirin, oxygen uptake etc.Medicine group 32 examples wherein of the present invention add at random uses Chinese medicinal composition preparation of the present invention, and each 4,3 times on the one, oral medication, 4 weeks of the course of treatment.
1.5 observation index is with reference to the clinical diagnosis standard of national idiopathic pulmonary interstitial fibrosis, dyspnea, dry cough, blood oxygen saturation, chest X ray or CT recover normal situation of change when leaving hospital with healing before treating, and the influence of hospital day etc. is observed.
2 results
After treatment finished, the average of dyspnea, cough, body temperature, cyanosis and respiratory frequency was all less than matched group in the medicine group symptom and sign of the present invention, and two groups of differences have statistical significance (seeing Table 1).Two groups of hypoxemia and rabat again often between relatively, medicine class mean of the present invention is less than matched group, difference has statistical significance (seeing Table 2).Two groups of hospital stayss, relatively medicine class mean of the present invention was less than matched group, and difference has statistical significance (seeing Table 3).
Table 1 liang group symptom and sign again often between relatively
Symptom and sign again often between (my god)
Dyspnea cough body temperature cyanosis respiratory frequency
Medicine group 5.14 of the present invention ± 3.48 5.03 ± 3.54 3.18 ± 3.29 5.02 ± 3.29 5.40 ± 3.28
Matched group 8.57 ± 4.25 9.16 ± 3.98 6.50 ± 4.83 7.83 ± 3.90 7.74 ± 3.65
P value＜0.05＜0.05＜0.05＜0.05＜0.05
Table 2 liang group hypoxemia and rabat again often between relatively
Hypoxemia and rabat again often between (my god)
The hypoxemia rabat
Medicine group 5.14 of the present invention ± 3.48 13.03 ± 9.54
Matched group 8.57 ± 4.25 20.87 ± 10.98
P value＜0.05＜0.05
Table 3 liang group hospital day relatively
Hospital stays (my god)
Group medicine group of the present invention matched group P value
Average 24.5 ± 3.43 35.03 ± 6.47＜0.05
3 conclusions
Chinese medicinal composition preparation of the present invention has the effect that the restrictive ventilatory disorder that improves pulmonary fibrosis and gas interchange disturbance, promotion fibrous tissue absorb, point out Chinese medicine composition of the present invention to can be used for the treatment of pulmonary fibrosis, especially for the treatment of the Secondary cases pulmonary fibrosis due to the viral infection, the treatment of the pulmonary fibrosis due to infecting in particular for SARS virus.
List of references
1, Huang Junqian, Li Yongchun. the pathogenesis of interstitial pulmonary fibrosis and treatment present situation. Shandong medical journal, 2002,17 (1): 90
2、Gulsvik?A.，Kjelsberg?A.，et?al.High-dose?intravenous?methylprednisolone?pulsetherpy?as?initial?treatment?in?eryptogenic?fibrosing?alveolitis：a?pilot?study[J].Respiration，1986，50：252
3、Dougas?W.，Ryu?JH.，Swensen?SJ.Et?al.Colchicine?versus?prednisone?in?thetreatment?of?idiopathic?pulmonary?fibrosis：a?randomized?prospective?study[J].AmJ?Respir?Crit?Care?Med.，1998，158：220
4、Nguyen?L.，Ward?WF.，Tsao?CH.，et?al.Captopril?inhibits?proliferation?of?human?lungfibroblasts?in?culture：a?potential?antifibrotic?mechanism[J].Proc?Soc?Exp?BiolMed.，1994，205：80
5, Li Yongchun, what ice, Wang Haibin etc.Erythromycin is to the influence [J] of lung fibrosis in rats nuclear factor kB activity and mRNA expression of cytokines.China's tuberculosis and breathing magazine, 1999,22:725
6、Ziesche?R.，Hofbauer?E.，Wittmann?K.，et?al.A?preliminary?study?of?long-termtreatment?with?interferon?Gamma-1b?and?low-dose?prednisolone?in?patients?withidiopathic?pulmonary?fibrosis[J].N?Engl?J.Med.，1999，341：1264
7 .78 such as Xiao Zhenglun example severe acute respiratory syndrome case clinical analysis. Chinese tuberculosis and breathe magazine, 2003; 26 (6);
8, Ceng Qingsi etc. the image performance of severe acute respiratory syndrome. Chinese tuberculosis and breathe magazine, 2003; 26 (6):
9、Lee?N，Hui?D，Wu?A，et?al.Amajor?outbreak?of?severe?acute?respiratory?syndrome?inHong?Kong.N?Engl?J?Med?2003；published?at?www.nejm.org.on?April?7，2003.
10、Poutanen?SM，Low?DE，Henry?B，et?al.Identification?of?severe?acute?respiratorysyndrome?in?Canada.N?Engl?J?Med?2003；published?at?www.nejm.org.on?Mar31，2003.
11, turbulent waves, Wang Jianwei, Sun Yilin, etc. electron microscopic observation is found chlamydia sample and coronavirus sample granule from atypical pneumonia patient postmortem specimen. Chinese Medical Journal, 2003,83:632-636.
Claims (6)
1. the application of Chinese medicine composition in preparation treatment pulmonary fibrosis medicine for the treatment of chronic hepatitis Bhepatic fibrosis, this Chinese medicine composition is made according to conventional method with following raw materials according: Carapax Trionycis 110-130 part, Radix Paeoniae Rubra 80-90 part, Radix Angelicae Sinensis 40-60 part, Radix Notoginseng 40-60 part, Radix Codonopsis 80-90 part, Radix Astragali 80-90 part, Placenta Hominis 40-50 part, Cordyceps 20-30 part, Radix Isatidis 130-150 part, Fructus Forsythiae 130-150 part, Rhizoma Curcumae 20-30 part.
2. purposes as claimed in claim 1, wherein said Chinese medicine composition is made with following raw materials according: 25 parts of 120 parts of Carapax Trionycis, 85 parts of Radix Paeoniae Rubra, 50 parts of Radix Angelicae Sinensis, 50 parts of Radix Notoginseng, 85 parts of Radix Codonopsis, 85 parts of the Radixs Astragali, 45 parts of Placenta Hominiss, 25 parts of Cordyceps, 140 parts of Radix Isatidis, Fructus Forsythiae 140g part, Rhizoma Curcumae.
3. purposes as claimed in claim 1 or 2, wherein said Chinese medicine composition is made according to following method: Carapax Trionycis, Radix Notoginseng, Radix Paeoniae Rubra, Cordyceps, Placenta Hominis are ground into fine powder; With Radix Angelicae Sinensis, Rhizoma Curcumae, Fructus Forsythiae distillating extracting oil, the aqueous solution after the distillation is stand-by, and medicinal residues are decocted with water 1-2 hour, filters, and filtrate and above-mentioned aqueous solution merge; Radix Codonopsis, the Radix Astragali and Radix Isatidis three flavors are decocted with water three times, each 1-2 hour, merge three times decocting liquid, filter to get filtrate; All filtrates and aqueous solution are merged, after the centrifugal roguing, under 50 ℃, be evaporated to the thick paste shape of relative density 1.25-1.30, vacuum drying becomes dry extract, is ground into fine powder, and with the fine powder and the right amount of auxiliary materials mixing of Carapax Trionycis, Radix Notoginseng, Radix Paeoniae Rubra, Cordyceps, the Placenta Hominis five tastes, make granule and dry, the volatile oil that adds above-mentioned Radix Angelicae Sinensis, Rhizoma Curcumae, Fructus Forsythiae three flavors again, mixing, compacting is in flakes.
4. as any described purposes among the claim 1-3, wherein said pulmonary fibrosis comprises Secondary cases pulmonary fibrosis and idiopathic pulmonary fibrosis.
5. purposes as claimed in claim 4, wherein said pulmonary fibrosis are by the Secondary cases pulmonary fibrosis due to the viral infection.
6. purposes as claimed in claim 5, wherein said pulmonary fibrosis are by the Secondary cases pulmonary fibrosis due to the SARS virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031462774A CN1173731C (en) | 2003-07-08 | 2003-07-08 | Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031462774A CN1173731C (en) | 2003-07-08 | 2003-07-08 | Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1460514A CN1460514A (en) | 2003-12-10 |
| CN1173731C true CN1173731C (en) | 2004-11-03 |
Family
ID=29591392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031462774A Expired - Fee Related CN1173731C (en) | 2003-07-08 | 2003-07-08 | Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1173731C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100394946C (en) * | 2004-12-17 | 2008-06-18 | 上海中医药大学 | Traditional Chinese medicine formulation for improving pulmonary fibrosis |
| CN105853911A (en) * | 2016-04-14 | 2016-08-17 | 张全月 | Prescription for treating cytomegalovirus infectious heptitis |
-
2003
- 2003-07-08 CN CNB031462774A patent/CN1173731C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1460514A (en) | 2003-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1189201C (en) | Externally applied Chinese medicine for treating osteoarthropathy and its prepn process | |
| CN1173731C (en) | Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS | |
| CN101721494B (en) | Traditional Chinese medicine for treating cervical tuberculous lymphadenitis | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN101249228B (en) | Mongolian medicine for curing lung interstitial substance fibrosis | |
| CN1720936A (en) | Medicine for treating breadth gasp, cough, asthma and phelgm | |
| CN100346812C (en) | Medicine for treating hyperplasia of mammary glands and fibroadenoma of breast and prepn. technique | |
| CN1593587A (en) | Lung nourishing and regulating pill for treating lung system diseases and preparation method thereof | |
| CN101239175A (en) | Lung comforting plaster and preparation thereof | |
| CN1281241C (en) | Medicine for treating chronic bronchitis and its preparation method | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN1943691A (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| CN1136879C (en) | Combined Chinese and Western medicine for treating chronic bronchitis in catabasis | |
| CN1136935A (en) | Medicinal granule for treating hemiparalysis and producing process thereof | |
| CN101062292A (en) | Medicine for treating cancer and preventing lung cancer and preparing method thereof | |
| CN1839974A (en) | Medicine composition for treating rheumatoid disease and method for preparing the same | |
| CN1513539A (en) | Preparation technology of supplementing kind capsule | |
| CN1579434A (en) | Chaihuang Tonic and its preparation method | |
| CN1283310C (en) | Chinese medicinal preparation for treating coronarg heart disease arrhythmia and its manufacturing process | |
| CN105213967A (en) | A kind of Chinese medicine preparation for the treatment of malignant tumor | |
| CN117180378A (en) | Fructus cnidii detoxification formula and application thereof | |
| CN103041269B (en) | A kind of Chinese medicine for the treatment of postoperative pneumonia | |
| CN103041266B (en) | Medicine for treating pediatric postoperative pneumonia | |
| CN115814030A (en) | Traditional Chinese medicine composition for preventing and treating new coronavirus and application thereof | |
| CN102488748A (en) | External traditional Chinese medicine composition for treating parotitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041103 Termination date: 20100708 |